Enzyme Therapy (ET) has been practiced successfully for a wide range of disease states. Often, the enzymes used are fungal based because they are effective over a wide range (mostly acidic due to the digestive environment they are formulated to work in) of pHs. This has been fruitful. In fact, many of the enzymes used are touted for their ability to function well in the gastric environment and are considered useful for that purpose. However, what has been ignored is that there are diseases that can be associated with having too low a pH in the body. This paper discusses the formulation of an enzyme supplement that can be used to alter the pH of the body. The implications of this are staggering and will certainly garner much attention over the next few years. Additionally, data is presented demonstrating that the special, food grade enzymes can work in an alkaline environment. The present work demonstrates the feasibility of creating an enzyme system capable of being functional at higher pHs and the possibilit y that the pH change can have a genomeceutical effect. (1)
Acidosis is a state where the pH of the blood is abnormally low (blood is usually at a pH of 7.3). Webster's states it is "an abnormal condition characterized by reduced alkalinity of the blood and of the body tissues." (2) There are a large number of clinical conditions which have been associated with acidosis. (3)
For instance, inhibition of mesangial iNOS by reduced extracellular pH is associated with uncoupling of NADPH oxidation. Chronic renal failure is associated with metabolic acidosis and down-regulation of intrarenal nitric oxide (NO) synthesis. It has been hypothesized that acidosis may impair the intrarenal NO synthesis. The effects of alterations in extracellular pH were examined on inducible NO synthesis in murine mesangial cells (MMC) in culture. It was shown that acidosis impairs iNOS activity in MMC by a post-translational mechanism that involves uncoupling of NADPH oxidation.
Acidosis has also been implicated in childhood diseases. (4) Mitochondrial cytopathies are caused by genetic alterations of nuclear- or mitochondrial-encoded genes involved in the synthesis of subunits of the electron transport chain. Mutations of mitochondrial DNA are associated with a wide range of clinical presentations. Typically, the pathology is so complex it has been hard to ferret out exactly what is happening. However, it is well known that nucleic acids require a defined pH range to function correctly. Indeed, if the pH around DNA is altered too significantly, the actual shape and therefore function of the DNA can be affected. During metabolic acidosis, increased renal ammoniagenesis and bicarbonate synthesis are sustained by the increased expression of various transport proteins and key enzymes of glutamine metabolism. Altering the pH may be a way of using a genomceutical (1) to change the expression of desirable enzymes. (5)
Also in children, initial screenings include tests for acidosis. Neuro-degenerative diseases in children (6) and other diseases have been linked to acid-base problems. (7) Genetic disorders of acid-base transporters...
This is a preview. Get the full text through your school or public library.